SGLT2 Inhibitors: The Sweet Success for Kidneys

被引：31

作者：

Dharia, Atit ^{[1
,2
]}

Khan, Abid ^{[1
,2
]}

Sridhar, Vikas S. ^{[1
,2
]}

Cherney, David Z., I ^{[1
,2
]}

机构：

[1] Univ Hlth Network, Dept Med, Div Nephrol, Toronto, ON, Canada

[2] Univ Toronto, Dept Med, Toronto, ON, Canada

来源：

ANNUAL REVIEW OF MEDICINE | 2023年 / 74卷

基金：

加拿大健康研究院;

关键词：

sodium glucose cotransporter 2 inhibitor; kidney outcomes; diabetic kidney disease; nondiabetic kidney disease; acute kidney injury; COTRANSPORTER; 2; INHIBITORS; GLUCOSE CO-TRANSPORTER-2 INHIBITORS; TYPE-2; DIABETES-MELLITUS; CARDIOVASCULAR OUTCOMES; DAPAGLIFLOZIN; DISEASE; EMPAGLIFLOZIN; PROTECTION; SAFETY; ERTUGLIFLOZIN;

D O I：

10.1146/annurev-med-042921-102135

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) were originally developed as antidiabetic agents, with cardiovascular (CV) outcome trials demonstrating improved CV outcomes in patients with type 2 diabetes mellitus (T2D). Secondary analyses of CV outcome trials and later dedicated kidney outcome trials consistently reported improved kidney-related outcomes independent of T2D status and across a range of kidney function and albuminuria. Importantly, SGLT2 inhibitors are generally safe and well tolerated, with clinical trials and real-world analyses demonstrating a decrease in the risk of acute kidney injury. The kidney protective effects of SGLT2 inhibitors generally extend across different members of the class, possibly on the basis of hemodynamic, metabolic, anti-inflammatory, and antifibrotic mechanisms. In this review, we summarize the effects of SGLT2 inhibitors on kidney outcomes in diverse patient populations.

引用

页码：369 / 384

页数：16

共 99 条

[21] Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin [J].

Cherney, David Z. I. ;

Cooper, Mark E. ;

Tikkanen, Ilkka ;

Pfarr, Egon ;

Johansen, Odd Erik ;

Woerle, Hans J. ;

Broedl, Uli C. ;

Lund, Soren S. .

KIDNEY INTERNATIONAL, 2018, 93 (01) :231-244

[22] Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial [J].

Cherney, David Z. I. ;

Zinman, Bernard ;

Inzucchi, Silvio E. ;

Koitka-Weber, Audrey ;

Mattheus, Michaela ;

von Eynatten, Maximilian ;

Wanner, Christoph .

LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (08) :610-621

[23] The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus [J].

Cherney, David Z. I. ;

Perkins, Bruce A. ;

Soleymanlou, Nima ;

Har, Ronnie ;

Fagan, Nora ;

Johansen, Odd Erik ;

Woerle, Hans-Juergen ;

von Eynatten, Maximilian ;

Broedl, Uli C. .

CARDIOVASCULAR DIABETOLOGY, 2014, 13

[24] Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease [J].

Chertow, Glenn M. ;

Vart, Priya ;

Jongs, Niels ;

Toto, Robert D. ;

Gorriz, Jose Luis ;

Hou, Fan Fan ;

McMurray, John J. V. ;

Correa-Rotter, Ricardo ;

Rossing, Peter ;

Sjostrom, C. David ;

Stefansson, Bergur V. ;

Langkilde, Anna Maria ;

Wheeler, David C. ;

Heerspink, Hiddo J. L. .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (09) :2352-2361

[25] Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV [J].

Dagogo-Jack, Samuel ;

Cannon, Christopher P. ;

Cherney, David Z., I ;

Cosentino, Francesco ;

Liu, Jie ;

Pong, Annpey ;

Gantz, Ira ;

Frederich, Robert ;

Mancuso, James P. ;

Pratley, Richard E. .

DIABETES OBESITY & METABOLISM, 2022, 24 (07) :1245-1254

[26] International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors [J].

Danne, Thomas ;

Garg, Satish ;

Peters, Anne L. ;

Buse, John B. ;

Mathieu, Chantal ;

Pettus, Jeremy H. ;

Alexander, Charles M. ;

Battelino, Tadej ;

Javier Ampudia-Blasco, F. ;

Bode, Bruce W. ;

Cariou, Bertrand ;

Close, Kelly L. ;

Dandona, Paresh ;

Dutta, Sanjoy ;

Ferrannini, Ele ;

Fourlanos, Spiros ;

Grunberger, George ;

Heller, Simon R. ;

Henry, Robert R. ;

Kurian, Martin J. ;

Kushner, Jake A. ;

Oron, Tal ;

Parkin, Christopher G. ;

Pieber, Thomas R. ;

Rodbard, Helena W. ;

Schatz, Desmond ;

Skyler, Jay S. ;

Tamborlane, William V. ;

Yokote, Koutaro ;

Phillip, Moshe .

DIABETES CARE, 2019, 42 (06) :1147-1154

[27] Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers [J].

Dekkers, Claire C. J. ;

Petrykiv, Sergei ;

Laverman, Gozewijn D. ;

Cherney, David Z. ;

Gansevoort, Ron T. ;

Heerspink, Hiddo J. L. .

DIABETES OBESITY & METABOLISM, 2018, 20 (08) :1988-1993

[28] Effects of ACEIs and ARBs on the Residual Renal Function in Peritoneal Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials [J].

Ding, Lei ;

Yang, Jingjuan ;

Li, Lizhu ;

Yang, Yi .

BIOMED RESEARCH INTERNATIONAL, 2020, 2020

[29] Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis [J].

Donnan, Jennifer R. ;

Grandy, Catherine A. ;

Chibrikov, Eugene ;

Marra, Carlo A. ;

Aubrey-Bassler, Kris ;

Johnston, Karissa ;

Swab, Michelle ;

Hache, Jenna ;

Curnew, Daniel ;

Hai Nguyen ;

Gamble, John-Michael .

BMJ OPEN, 2019, 9 (01)

[30] CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis [J].

Ferrannini, Ele ;

Mark, Michael ;

Mayoux, Eric .

DIABETES CARE, 2016, 39 (07) :1108-1114

← 1 2 3 4 5 6 7 8 9 10 →